Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Hiran Orgochem Ltd

    Incorporated in 1983, Mumbai based Hiran Orgochem Ltd is a integrated manufacturer of active pharmaceutical ingredients and formulations. It has focused on Manufacturing the Qui

  • No Image
    HLL Lifecare Ltd

    HLL Lifecare Ltd is a 100% Government of India owned entity was incorporated in 1966 for the production of male contraceptive sheaths and commenced operations

  • No Image
    ICBio Clinical Research Pvt Ltd

    ICBio CRO is one of the leading Contract Research Organization, based in Bangalore, INDIA, established in 2008, conducting clinical trials in India and the Emerging Markets acro